3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Prostatic Neoplasms
48
Prostatic Neoplasms, Castration-Resistant
3
Adenocarcinoma
3
Urogenital Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Diseases
2
Non-metastatic Castration-resistant Prostate Cancer
2
Neoplasms
2
Neoplasm Metastasis
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Metastatic Castration-resistant Prostate Cancer
2
Male Urogenital Diseases
2
Bulbo-Spinal Atrophy, X-Linked
2
Biochemically Recurrent Prostate Cancer
2
Urogenital Diseases
1
Triple Negative Breast Neoplasms
1
Sleep Initiation and Maintenance Disorders
1
Refractory or Relapsed Solid Tumors
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Neoplasms by Site
1
Metastatic Hormone-sensitive Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
High-Risk Localized Prostate Cancer
1
Granulosa cell tumor of the ovary
1
Genital Diseases, Male
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Interventions
ruxolitinib
23
Cyclophosphamide
13
Whole-Body Irradiation
10
Tacrolimus
9
Mycophenolic Acid
9
fludarabine phosphate
8
fludarabine
8
Stem Cell Transplantation
8
Specimen Handling
7
Peripheral Blood Stem Cell Transplantation
7
Busulfan
5
Azacitidine
5
navitoclax
4
Sirolimus
4
Melphalan
4
Biopsy
4
luspatercept
3
fedratinib
3
Methotrexate
3
Cyclosporine
3
venetoclax
2
selinexor
2
parsaclisib
2
letermovir
2
itacitinib
2
bomedemstat
2
Injections
2
INCB057643
2
INCB039110
2
Hematopoietic Stem Cell Transplantation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
darolutamide
×
1 year
×
Clear all
No trials found.